For HIV-1 treatment in HTE* adults

If their regimen fails,
we'll be there

A first-in-class treatment with a novel mechanism of action1,2

For HIV-1 treatmentin HTE* adults

If their regimen fails,
we'll be there

A first-in-class
treatment with a novel
mechanism of action1,2

INDICATION
RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.

*Heavily treatment-experienced.

354 Days to the RUKOBIA National Broadcast Event

Read more »

DISCOVER RUKOBIA

BRIGHTE CLINICAL
TRIAL

Learn about the efficacy and safety of RUKOBIA in BRIGHTE

Read more »

BRINGING RUKOBIA TO
PATIENTS

Find out about the commitment behind RUKOBIA

Read more »

ViiV MEDICAL
INFORMATION

View our medical information library if you have a question about RUKOBIA

Read more »

A DEEPER LOOK AT RUKOBIA

RISKS & SIDE EFFECTS

Get information about the possible risks and side effects, including warnings and precautions and rates of discontinuation

Read more »

DOSING AND DRUG
INTERACTIONS

Learn about administering RUKOBIA

Read more »

EDUCATIONAL RESOURCES

View additional details about RUKOBIA in the full Prescribing Information

Read more »

References:

  1. Data on file, ViiV Healthcare.
  2. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. US Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Updated December 18, 2019. Accessed March 3, 2020.

FSTWCNT200005